Prestige Management Fights Back Following Biosimilar Rejection
CEO And COO Buy Up nearly 140,000 Shares To ‘Reinforce Trust’
Prestige BioPharma’s top brass are looking to restore shareholder confidence following the surprise failure of their trastuzumab biosimilar before the EMA’s CHMP.
